cl-316243 and Hypertrophy

cl-316243 has been researched along with Hypertrophy* in 2 studies

Other Studies

2 other study(ies) available for cl-316243 and Hypertrophy

ArticleYear
CL316,243, a β3-adrenergic receptor agonist, induces muscle hypertrophy and increased strength.
    Scientific reports, 2016, 11-22, Volume: 5

    Studies in vitro have demonstrated that β3-adrenergic receptors (β3-ARs) regulate protein metabolism in skeletal muscle by promoting protein synthesis and inhibiting protein degradation. In this study, we evaluated whether activation of β3-ARs by the selective agonist CL316,243 modifies the functional and structural properties of skeletal muscles of healthy mice. Daily injections of CL316,243 for 15 days resulted in a significant improvement in muscle force production, assessed by grip strength and weight tests, and an increased myofiber cross-sectional area, indicative of muscle hypertrophy. In addition, atomic force microscopy revealed a significant effect of CL316,243 on the transversal stiffness of isolated muscle fibers. Interestingly, the expression level of mammalian target of rapamycin (mTOR) downstream targets and neuronal nitric oxide synthase (NOS) was also found to be enhanced in tibialis anterior and soleus muscles of CL316,243 treated mice, in accordance with previous data linking β3-ARs to mTOR and NOS signaling pathways. In conclusion, our data suggest that CL316,243 systemic administration might be a novel therapeutic strategy worthy of further investigations in conditions of muscle wasting and weakness associated with aging and muscular diseases.

    Topics: Adrenergic beta-3 Receptor Agonists; Animals; Dioxoles; Gene Expression Regulation; Hypertrophy; Male; Mice, Inbred C57BL; Muscle Fibers, Skeletal; Muscle Strength; Muscle, Skeletal; Nitric Oxide Synthase Type I; Signal Transduction; TOR Serine-Threonine Kinases

2016
Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a beta3-adrenoceptor agonist.
    Biochemical pharmacology, 1997, Jul-01, Volume: 54, Issue:1

    In a previous study, we demonstrated that chronic treatment with a new beta3-adrenoceptor agonist, CL 316,243 [disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-ben zodioxazole-2,2-dicarboxylate], promoted thermogenesis, caused the appearance of multilocular adipocytes in white adipose tissue (WAT), and retarded development of obesity in young rats eating a high-fat diet (Himms-Hagen et al., Am J Physiol 266: R1371-R1382, 1994). Objectives of the present study were to find out whether CL 316,243 could reverse established diet-induced obesity in rats and to identify the multilocular adipocytes that appeared in WAT. Infusion of CL 316,243 (1 mg/kg/day) reduced abdominal fat, with a decrease in enlarged adipocyte size but no loss of white adipocytes. The resting metabolic rate increased by 40-45%, but food intake was not altered. Abundant densely stained multilocular brown adipocytes expressing uncoupling protein (UCP) appeared in retroperitoneal WAT, in which a marked increase in protein content occurred. UCP content of interscapular brown adipose tissue (BAT) was also increased markedly. We suggest that the substantial increase in the resting metabolic rate induced by CL 316,243 occurs in brown adipocytes in both BAT and WAT. The origin of the brown adipocytes that appeared in WAT is uncertain. They may have been small brown preadipocytes, expressing beta3-adrenoceptors but with few mitochondria and little or no UCP, that were induced to hypertrophy by the beta3-agonist.

    Topics: Adipose Tissue; Adipose Tissue, Brown; Adrenergic beta-Agonists; Animals; Body Weight; Carrier Proteins; Dietary Fats; Dioxoles; Epididymis; Hypertrophy; Immunohistochemistry; Ion Channels; Male; Membrane Proteins; Mitochondrial Proteins; Obesity; Organ Size; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Receptors, Adrenergic, beta-3; Retroperitoneal Space; Uncoupling Protein 1

1997